BioCentury
ARTICLE | Clinical News

Daxas roflumilast: Additional Phase III data

November 16, 2009 8:00 AM UTC

Additional data from the double-blind, international Phase III AURA trial in 1,523 patients showed that that once-daily 500 ug oral Daxas for 52 weeks significantly improved mean pre-bronchodilator FE...